Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31409661 | 0.80 | QPCT (0.41) | S1PR1DYRK1AGSK3BQPCTCLK1 | |
| SCHEMBL31409705 | 0.74 | DYRK1A (0.36) | DYRK1AGSK3BKCNH2SCN9ACLK1 | |
| SCHEMBL31409660 | 0.70 | TP53 (0.38) | DYRK1AGSK3BQPCT | |
| SCHEMBL15084530 | 0.69 | CDK5 (0.41) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL3192003 | 0.66 | LTA4H (0.41) | DYRK1A | |
| SCHEMBL22686159 | 0.65 | KCNH2 (0.42) | KCNH2SCN9A | |
| SCHEMBL22502476 | 0.64 | KMO (0.34) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL29378128 | 0.64 | KMO (0.34) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL31409587 | 0.64 | SLC6A4 (0.38) | DYRK1AGSK3BKCNH2SCN9ACDK5 | |
| SCHEMBL29331748 | 0.64 | KCNH2 (0.41) | KCNH2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025026997-A1 | SUBSTITUED BICYCLIC HETEROCYCLIC YAP-TEAD AND/OR TAZ-TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2025-02-06 | — | — | WO | disclosed |